eoadjuvant fractionated stereotactic radiotherapy followed by surgical resection for brain metastases: efficacy and safety study

Mitsuya Koichi0 个研究点目标入组 57 人开始时间: 2022年5月2日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1. Distinct number of brain metastases <= 4, One with surgical indication
•2. Index lesion should be >= 2 cm and <= 5 cm in largest dimension, and require resection. Index lesions will be treated with SRS and surgery.
•3. All of index lesion exist cerebrum or cerebellar.
•4. No radiographic evidence of leptomeningeal disease
•5. Eastern Cooperative Oncology Group performance status (ECOG-PS) scores of 0 to 2 and 3 if a result of only neurologic symptoms caused by the tumor.
•6. Primary tumors were non-small-cell lung cancer as well as cancers of the breast, colon, kidney, ovary, uterine cervix and corpus, stomach, or esophagus.
•7. Primary cancer and/or extra cranial metastases is not progressive critically.
•8. Age 20 to 79 years.
•9. Patients who have received prior whole brain radiotherapy and/or craniotomy.
•10. WBC >= 2,000 /mm3, Hb >= 8.0 g/dl, PLT >=10x104 /mm3, AST <= 120 IU/l, ALT <= 120 IU/l,
•CRE <= 1.5 mg/dl
•11. All patients provided written informed consent.

•Documented history of active other malignancy
•Pregnant, breastfeeding, or woman of childbearing
•age without effective contraception
•Patient with psychiatric disorder
•Contraindication to gadolinium injection
•Emergent surgery needed condition (impending cerebral herniation or acute hydrocephalus)

发起方

Mitsuya Koichi